차세대 항체 치료제 시장(제2판) - 업계 동향과 세계 예측(-2035년) - 약제별, 신규 항체별, 표적 질환별, 치료법별, 투여 경로별, 주요 지역별, 주요 기업별

Next Generation Antibody Therapeutics Market

As per Roots Analysis, the next generation antibody therapeutics market is estimated to grow from USD 843 million in the current year to USD 2,161 million by 2035, at a CAGR of 9.87% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Drugs

• Adcetris
• Kadcyla
• ELZONRIS
• Besponsa
• LYMPHIR
• Fibromun
• Nidlegy
• Iomab-B
• TLX 591

Type of Novel Antibody

• Radioisotope Immunoconjugates
• Immunocytokines
• Immunotoxins

Target Indication

• Previously Untreated Systemic Anaplastic Large Cell Lymphoma (SALCL) or other CD30-expressing Peripheral T-cell Lymphomas (PTCL)
• Classical Hodgkin Lymphoma
• Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or
• CD30-expressing Mycosis Fungoides (MF)
• Diffuse Large B-cell Lymphoma
• Relapsed or Refractory B-cell precursor Acute
• Lymphoblastic Leukemia
• HER2-positive breast cancer
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Locally Advanced, Melanoma / Stage III B / C Melanoma
• Relapsed or Refractory Cutaneous T-cell Lymphoma
• Relapsed / Refractory Acute Myeloid
• Leukemia
• Metastatic Castration-resistant Prostate Cancer
• Soft Tissue Sarcoma

Type of Therapy

• Combination Therapy
• Monotherapy

Route of Administration

• Intratumoral
• Intravenous

Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa

Novel Antibody Therapies Market: Growth and Trends

Antibodies, or immunoglobulins, are proteins generated by the immune system that identify and attach to particular antigen markers on cells or tissues, acting as the primary defense against various ailments. Utilizing the accuracy of antibody-antigen interactions, innovative antibody treatments have shown considerable promise in enhancing patient results. In recent years, numerous innovative antibody treatments received approval from the USFDA, signifying notable progress in the treatment of a range of illnesses, such as metabolic disorders, cardiovascular issues, cancer, and rare diseases. These authorizations demonstrate the effectiveness of biotechnological methods in tackling significant healthcare issues and underscore the role of antibody therapies in contemporary medicine. Increased funding and investments, along with partnership initiatives, are vital for the research and development of new antibodies targeting various disorders. Moreover, numerous advanced technologies are transforming the identification and development of new therapies, fundamentally changing treatment approaches.

Novel Antibody Therapies Market: Key Insights

The report delves into the current state of the global novel antibody therapies market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Over 70 radioisotope immunoconjugates are approved / being investigated across different stages of development for the treatment of various diseases; of these, >80% of the therapies are in early-stages of development.

• Close to 70% of the monotherapies can be administered intravenously; of these, majority (96%) of the therapies are under clinical stages of development.
• Over 35 immunocytokines are currently approved / being investigated across various stages of development for the treatment of various diseases; of these, nearly 60% of the therapies are in early-stages of development.
• Presently, over 45% of immunocytokines in early stages of development are in conjugation with IL-2 and IL-15 types of cytokine; of these, majority (80%) of the therapies can be administered as combination therapy.
• Nearly 60 immunotoxins are currently approved / being investigated across different stages of development for the treatment of various diseases; of these, more than 45% of the therapies are in early-stages of development.
• Presently, nearly 80% of the late-stage immunotoxins (phase II and phase II / III) are administered via injections; further, 56% immunotoxins are in conjugation with microbial toxins.
• Most of the trials were registered in 2024; notably, a significant proportion (72%) of the total trials are currently recruiting patients for the investigation of novel antibody therapies.
• The growing scientific literature highlights the active involvement of stakeholders in the research and development of novel antibody therapies; close to 35% of the articles were published in the previous year.
• Majority of the patent assignees are non-industry players; however, over the past few years, the contribution of industry players in the patent filing activity has also increased.

• Close to 20% deals inked in this domain are supply agreements; of these, 44% agreements were signed in 2022 in order to address the growing demand for novel antibodies.
• Using our proprietary forecast model, we estimated the current size of the global novel antibody therapies market, taking into consideration the historical trends, data and inputs obtained from exhaustive research.

• Currently, the global novel antibody therapies market is dominated by drugs that are intended to target HER2-positive breast cancer, followed by classical Hodgkin lymphoma.

Novel Antibody Therapies Market: Key Segments

Adcetris Drug Captures the Largest Share in the Next Generation Antibody Therapeutics Market

Currently, Adcetris holds the higher market share of close to 45% due to its early approvals and proven effectiveness in hematologic cancers. LYMPHIR is expected to expand at an increased CAGR of 18% throughout the forecast period.

Immunotoxins Segment Holds the Majority of the Next Generation Antibody Therapeutics Market Share

The higher share of immunotoxins segment in the current year can be attributed to their superior targeted cytotoxicity and effectiveness against resistant cancer cells, as per next generation antibody therapeutics market forecast. Further, the immunocytokines sector is expected to exhibit the greatest growth potential, of over 40%, throughout the forecast period.

HER2-PBC Hold the Largest Share in the Next Generation Antibody Therapeutics Market

In the present year, HER2-PB captures a significant market share of nearly 45% in novel antibody therapies, driven by the growing incidence of HER2-positive breast cancer and the heightened use of targeted treatments that lead to substantial enhancements in patient outcomes and survival rates. The segment for relapsed or refractory cutaneous T-cell lymphoma is expected to exhibit the greatest growth potential of nearly 20% throughout the forecast period.

Monotherapy Dominates Next Generation Antibody Therapies Industry

Monotherapy segment holds most of the market share in the current year owing to its ability to provide highly specific targeting with fewer side effects. The combination therapy segment is likely to show the highest growth potential of close to 45%, during the forecast period.

Intravenous Route of Administration Dominates Next Generation Antibody Therapeutics Market Share

Currently, intravenous route of administration, the intravenous method dominates the market due to its capacity to provide a quick onset of action and improved bioavailability needed for effectively delivering large antibodies. The intratumoral method of delivery is expected to expand at a higher CAGR, fueled by its capacity to attain greater local drug levels, reduce systemic toxicity, and enhance treatment effectiveness

North America is Likely to Propel in the Next Generation Antibody Therapeutics Market in the Coming Years

According to our next generation antibody therapeutics market report, North America is likely to capture the majority (64%) of the market share in the current year, and this trend is unlikely to change in the future. This can be attributed to the strong healthcare system, innovative platforms for developing new antibody treatments, and a significant emphasis on personalized care, positioning this region at the forefront of novel antibody treatments.

Example Players in the Next Generation Antibody Therapeutics Market

• Actinium Pharmaceuticals
• Pfizer
• Philogen
• Roche
• Telix Pharmaceuticals
• Y-mAbs Therapies

Novel Antibody Therapies Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the novel antibody therapies market, focusing on key market segments, including [A] drug, [B] type of novel antibody, [C] target indication, [D] type of therapy, [E] route of administration and [F] leading players.
• Market Landscape 1: A detailed assessment of the current market landscape of radioisotope immunoconjugates, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of therapy, [C] route of administration, [D] dosing frequency, [E] type of radioisotope, [F] mode of administration, [G] mechanism of action [H] therapeutic area, [I] year of establishment, [J] company size, [K] location of headquarters, [L] type of developer and [M] most active players.
• Market Landscape 2: A detailed assessment of the current market landscape of immunocytokines, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of cytokine, [C] type of therapy, [D] dosing frequency, [E] mechanism of action, [F] mode of administration, [G] type of antigen / format, [H] route of administration [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
• Market Landscape 3: A detailed assessment of the current market landscape of immunotoxins, along with analyses based on several relevant parameters, including [A] stage of development, [B] type of toxin, [C] dosing frequency, [D] type of therapy, [E] mode of administration, [F] type of target, [G] mechanism of action, [H] route of administration, [I] therapeutic area, [J] year of establishment, [K] company size, [L] location of headquarters, [M] type of developer and [N] most active players.
• Company Profiles: In-depth profiles of prominent players based in regions, namely North America, Europe and Asia-Pacific that are currently involved in the engaged in the development of novel antibody therapies. Each profile features [A] a brief overview of the company, [B] its financial information, [C] details on its drug portfolio, [D] recent developments and an [E] informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating different novel antibody therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] study design, patient gender, [F] type of sponsor / collaborator, [G] most active industry and [H] geographical distribution.
• Publication Analysis: A detailed review of various peer-reviewed, scientific articles related to research on novel antibody therapies, based on relevant parameters, such as [A] year of publication, [B] type of publication, [C] popular publisher and [D] key journal.
• Patent Analysis: in-depth analysis of various patents that have been filed / granted for novel antibody therapies, taking into consideration parameters, such as [A] publication year, [B] type of patent, [C] type of applicant, [D] application year, [E] patent jurisdiction, patent age, [F] CPC symbols, [G] leading players.
• Partnerships and Collaborations An insightful analysis of the partnerships and collaborations established in gene therapy, non viral vector and viral vector manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
• Big Pharma Players: An analysis of big pharma players engaged in the field of novel antibody therapies, based on several relevant parameters, such as [A] developer strength, [B] portfolio strength, and [C] portfolio diversity.
• Recent Expansions: An analysis of the recent expansions undertaken by various companies in order to augment their respective capabilities related to viral vector and non viral vector manufacturing, based on several parameters, such as [A] year of expansion, [B] type of expansion, [C] type of vector, [D] application area and [E] geographical location of the expansion.
• Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of gene therapy, non viral vector and viral vector manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What is the current global capacity of developers?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Research Assumptions
  • 2.1.1. Market Landscape and Market Trends
  • 2.1.2. Market Forecast and Opportunity Analysis
  • 2.1.3. Comparative Analysis
• 2.2. Database Building
  • 2.2.1. Data Collection
  • 2.2.2. Data Validation
  • 2.2.3. Data Analysis
• 2.3. Project Methodology
  • 2.3.1. Project Commencement
  • 2.3.2. Secondary Research
    • 2.3.2.1. Annual Reports
    • 2.3.2.2. Academic Research Papers
    • 2.3.2.3. Company Websites
    • 2.3.2.4. Investor Presentations and Regulatory Filings
    • 2.3.2.5. White Papers
    • 2.3.2.6. Industry Publications
    • 2.3.2.7. Conferences and Seminars
    • 2.3.2.8. Government Portals
    • 2.3.2.9. Media and Press Releases
    • 2.3.2.10. Newsletters
    • 2.3.2.11. Industry and Paid Databases
    • 2.3.2.12. Roots Proprietary Databases
  • 2.3.3. Primary Research
  • 2.3.4. Data Analysis and Interpretation
  • 2.3.5. Market Forecast and Validation
  • 2.3.6. Report Compilation
• 2.4. Research Ethics and Integrity
• 2.5. Analytical Tools and Databases
• 2.6. Robust Quality Control Framework

3. MARKET DYNAMICS

• 3.1. Forecast Methodology
  • 3.1.1. Top-Down Approach
  • 3.1.2. Bottom-Up Approach
  • 3.1.3. Hybrid Approach
• 3.2. Market Assessment Framework
  • 3.2.1. Total Addressable Market (TAM)
  • 3.2.2. Serviceable Addressable Market (SAM)
  • 3.2.3. Serviceable Obtainable Market (SOM)
  • 3.2.4. Currently Acquired Market (CAM)
• 3.3. Forecasting Tools and Techniques
  • 3.3.1. Qualitative Forecasting
  • 3.3.2. Correlation
  • 3.3.3. Regression
  • 3.3.4. Extrapolation
  • 3.3.5. Convergence
  • 3.3.6. Sensitivity Analysis
  • 3.3.7. Scenario Planning
  • 3.3.8. Data Visualization
  • 3.3.9. Time Series Analysis
  • 3.3.10. Forecast Error Analysis
• 3.4. Key Considerations
  • 3.4.1. Demographics
  • 3.4.2. Economic Factors
  • 3.4.3. Competitive Landscape
  • 3.4.4. Government Regulations and Policies
  • 3.4.5. R&D Investment
  • 3.4.6. Technological Factors
  • 3.4.7. Industry Consolidation
  • 3.4.8. Supply Chain
  • 3.4.9. Market Access
  • 3.4.10. Pandemics / Unforeseen Disruptions Impact

4. MACRO-ECONOMIC INDICATORS

• 4.1. Market Dynamics
  • 4.1.1. Time Period
    • 4.1.1.1. Historical Trends
    • 4.1.1.2. Current and Forecasted Estimates
  • 4.1.2. Currency Coverage
    • 4.1.2.1. Overview of Major Currencies Affecting the Market
    • 4.1.2.2. Impact of Currency Fluctuations on the Industry
  • 4.1.3. Foreign Exchange Impact
    • 4.1.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 4.1.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.1.4. Recession
    • 4.1.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.1.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 4.1.5. Inflation
    • 4.1.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.1.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.1.6. Other Indicators
    • 4.1.6.1. War Impact Analysis
    • 4.1.6.2. Cross-border Dynamics
    • 4.1.6.3. Consumer Spendings and Gross Domestic Product
    • 4.1.6.4. Stock Market Performance

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. An Overview of Novel Antibody Therapies
• 6.2. Therapeutic Antibodies: Developmental Approaches
  • 6.2.1. Novel Antibody Therapies: Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
    • 6.2.1.1. Mechanism of Action of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
    • 6.2.1.2. Advantages of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
    • 6.2.1.3. Disadvantages of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
  • 6.2.2. Novel Antibody Therapies: TCR like Antibodies
    • 6.2.2.1. Mechanism of Action of TCR like Antibodies
    • 6.2.2.2. Advantages of TCR like Antibodies
    • 6.2.2.3. Disadvantages of TCR like Antibodies
  • 6.2.3. Novel Antibody Therapies: Radioisotope Immunoconjugates
    • 6.2.3.1. Mechanism of Action of Radioisotope Immunoconjugates
    • 6.2.3.2. Advantages of Radioisotope Immunoconjugates
    • 6.2.3.3. Disadvantages of Radioisotope Immunoconjugates
  • 6.2.4. Novel Antibody Therapies: Immunotoxins
    • 6.2.4.1. Mechanism of Action of Immunotoxins
    • 6.2.4.2. Advantages of Immunotoxins
    • 6.2.4.3. Disadvantages of Immunotoxins
  • 6.2.5. Novel Antibody Therapies: Intracellular Antibody
    • 6.2.5.1. Mechanism of Action of Intracellular Antibody
    • 6.2.5.2. Advantages of Intracellular Antibody
    • 6.2.5.3. Disadvantages of Intracellular Antibody
  • 6.2.6. Novel Antibody Therapies: Immunocytokines
    • 6.2.6.1. Mechanism of Action of Immunocytokines
    • 6.2.6.2. Advantages of Immunocytokines
    • 6.2.6.3. Disadvantages of Immunocytokines
• 6.3. Future Perspectives

7. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (RADIOISOTOPE IMMUNOCONJUGATES)

• 7.1. Chapter Overview
• 7.2. Market Landscape: Radioisotope Immunoconjugates
  • 7.2.1. Analysis by Stage of Development
  • 7.2.2. Analysis by Type of Therapy
  • 7.2.3. Analysis by Route of Administration
  • 7.2.4. Analysis by Dosing Frequency
  • 7.2.5. Analysis by Type of Radioisotope
  • 7.2.6. Analysis by Mode of Administration
  • 7.2.7. Analysis by Mechanism of Action
  • 7.2.8. Analysis by Therapeutic Area
• 7.3. Developer Landscape: Radioisotope Immunoconjugates
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Analysis by Type of Developer
  • 7.3.5. Most Active Players: Analysis by Number of Therapies

8. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (IMMUNOCYTOKINES)

• 8.1. Chapter Overview
• 8.2. Market Landscape: Immunocytokines
  • 8.2.1. Analysis by Stage of Development
  • 8.2.2. Analysis by Type of Cytokine
  • 8.2.3. Analysis by Type of Therapy
  • 8.2.4. Analysis by Dosing Frequency
  • 8.2.5. Analysis by Mechanism of Action
  • 8.2.6. Analysis by Mode of Administration
  • 8.2.7. Analysis by Type of Antigen / Format
  • 8.2.8. Analysis by Route of Administration
  • 8.2.9. Analysis by Therapeutic Area
• 8.3. Developer Landscape: Immunocytokines
  • 8.3.1. Analysis by Year of Establishment
  • 8.3.2. Analysis by Company Size
  • 8.3.3. Analysis by Location of Headquarters
  • 8.3.4. Most Active Players: Analysis by Number of Therapies

9. COMPETITIVE LANDSCAPE: NOVEL ANTIBODY THERAPEUTICS (IMMUNOTOXINS)

• 9.1. Chapter Overview
• 9.2. Market Landscape: Immunotoxins
  • 9.2.1. Analysis by Stage of Development
  • 9.2.2. Analysis by Type of Toxin
  • 9.2.3. Analysis by Dosing Frequency
  • 9.2.4. Analysis by Type of Therapy
  • 9.2.5. Analysis by Mode of Administration
  • 9.2.6. Analysis by Type of Target
  • 9.2.7. Analysis by Mechanism of Action
  • 9.2.8. Analysis by Route of Administration
  • 9.2.9. Analysis by Therapeutic Area
• 9.3. Developer Landscape: Immunotoxins
  • 9.3.1. Analysis by Year of Establishment
  • 9.3.2. Analysis by Company Size
  • 9.3.3. Analysis by Location of Headquarters
  • 9.3.4. Analysis by Type of Developer
  • 9.3.5. Most Active Players: Analysis by Number of Therapies

10. NOVEL ANTIBODY DEVELOPERS

• 10.1. Chapter Overview
  • 10.1.1. Actinium Pharmaceuticals
    • 10.1.1.1. Company Overview
    • 10.1.1.2. Management Team
    • 10.1.1.3. Contact Details
    • 10.1.1.4. Drug Portfolio
    • 10.1.1.5. Recent Developments and Future Outlook
  • 10.1.2. Pfizer
    • 10.1.2.1. Company Overview
    • 10.1.2.2. Management Team
    • 10.1.2.3. Contact Details
    • 10.1.2.4. Operating Business Segments
    • 10.1.2.5. Financial Information
    • 10.1.2.6. Drug Portfolio
    • 10.1.2.7. Recent Developments and Future Outlook
  • 10.1.3. Philogen
    • 10.1.3.1. Company Overview
    • 10.1.3.2. Management Team
    • 10.1.3.3. Contact Details
    • 10.1.3.4. Financial Information
    • 10.1.3.5. Drug Portfolio
    • 10.1.3.6. Recent Developments and Future Outlook
  • 10.1.4. Roche
    • 10.1.4.1. Company Overview
    • 10.1.4.2. Management Team
    • 10.1.4.3. Contact Details
    • 10.1.4.4. Operating Business Segments
    • 10.1.4.5. Financial Information
    • 10.1.4.6. Drug Portfolio
    • 10.1.4.7. Recent Developments and Future Outlook
  • 10.1.5. Telix Pharmaceuticals
    • 10.1.5.1. Company Overview
    • 10.1.5.2. Management Team
    • 10.1.5.3. Contact Details
    • 10.1.5.4. Financial Information
    • 10.1.5.5. Drug Portfolio
    • 10.1.5.6. Recent Developments and Future Outlook
  • 10.1.6. Y-mAbs Therapeutics
    • 10.1.6.1. Company Overview
    • 10.1.6.2. Management Team
    • 10.1.6.3. Contact Details
    • 10.1.6.4. Financial Information
    • 10.1.6.5. Drug Portfolio
    • 10.1.6.6. Recent Developments and Future Outlook

11. CLINICAL TRIAL ANALYSIS

• 11.1. Analysis Methodology and Key Parameters
• 11.2. Analysis by Trial Registration Year
• 11.3. Analysis by Trial Status
• 11.4. Analysis by Trial Registration Year and Trial Status
• 11.5. Analysis of Patients Enrolled by Trial Registration Year
• 11.6. Analysis of Patients Enrolled by Trial Status
• 11.7. Analysis by Trial Phase
• 11.8. Analysis by Study Design
• 11.9. Analysis by Target Patient Population
  • 11.9.1. Analysis by Patient Gender
  • 11.9.2. Analysis by Type of Sponsor / Collaborator
  • 11.9.3. Most Active Industry Players: Analysis by Number of Trials
  • 11.9.4. Analysis of Trials and Number of Patients Enrolled

12. PUBLICATION ANALYSIS

• 12.1. Analysis Methodology and Key Parameters
• 12.2. Novel Antibody Therapies: Publication Analysis
  • 12.2.1. Analysis by Year of Publication
  • 12.2.2. Analysis by Type of Publication
  • 12.2.3. Analysis by Most Popular Publisher
  • 12.2.4. Key Journals: Analysis by Number of Publications
  • 12.2.5. Key Journals: Analysis by Impact Factor

13. PATENT ANALYSIS

• 13.1. Analysis Methodology and Key Parameters
• 13.2. Novel Antibody Therapies: Patent Analysis
  • 13.2.1. Analysis by Publication Year
  • 13.2.2. Analysis by Type of Patent
  • 13.2.3. Analysis of Granted Patents and Patent Applications by Year
  • 13.2.4. Analysis by Type of Applicant
  • 13.2.5. Analysis by Application Year
  • 13.2.6. Analysis by Patent Jurisdiction
  • 13.2.7. Analysis by Patent Age
  • 13.2.8. Leading Industry Players: Analysis by Number of Patents
  • 13.2.9. Leading Non-Industry Players: Analysis by Number of Patents
  • 13.2.10. Leading Individual Assignees: Analysis by Number of Patents
  • 13.2.11. Patent Benchmarking: Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
  • 13.2.12. Patent Benchmarking: Analysis of Leading Industry Players by Patent Characteristics (CPC Codes)
  • 13.2.13. Patent Valuation: Analysis Methodology and Parameters
  • 13.2.14. Patent Valuation: Analysis by Relative Valuation

14. PARTNERSHIPS AND COLLABORATIONS

• 14.1. Chapter Overview
• 14.2. Partnership Models
• 14.3. Novel Antibody Therapeutics: Partnerships and Collaborations
  • 14.3.1. Analysis by Year of Partnership
  • 14.3.2. Analysis by Type of Partnership
  • 14.3.3. Analysis by Year and Type of Partnership
  • 14.3.4. Most Popular Drug: Analysis by Number of Partnerships
  • 14.3.5. Analysis by Types of Novel Antibody
  • 14.3.6. Analysis by Type of Partner
  • 14.3.7. Most Active Players: Analysis by Number of Partnerships
  • 14.3.8. Analysis by Therapeutic Area
  • 14.3.9. Analysis by Therapeutic Area and Type of Partnership
  • 14.3.10. Analysis by Geography
    • 14.3.10.1. Local and International Agreements
    • 14.3.10.2. Intracontinental and Intercontinental Agreements

15. BIG PHARMA PLAYERS

• 15.1. Analysis Methodology and Key Parameters
• 15.2. List of Big Pharma Players in Novel Antibody Therapies Domain
• 15.3. Scoring Criteria for Key Parameters
  • 15.3.1. Analysis by Developer Strength
  • 15.3.2. Analysis by Portfolio Strength
  • 15.3.3. Analysis by Portfolio Diversity
  • 15.3.4. Benchmarking: Spider Web Analysis
  • 15.3.5. Benchmarking: Harvey Ball Analysis
  • 15.3.6. Benchmarking: Wind Rose Chart

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges

17. GLOBAL NOVEL ANTIBODY THERAPIES MARKET

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Global Novel Antibody Therapies Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 17.4. Multivariate Scenario Analysis
  • 17.4.1. Conservative Scenario
  • 17.4.2. Optimistic Scenario
• 17.5. Key Market Segmentations

18. NOVEL ANTIBODY THERAPIES MARKET, BY DRUGS

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Novel Antibody Therapies Market: Distribution by Drugs
  • 18.3.1. Novel Antibody Therapies Market for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.2. Novel Antibody Therapies Market for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.3. Novel Antibody Therapies Market for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.4. Novel Antibody Therapies Market for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.5. Novel Antibody Therapies Market for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.6. Novel Antibody Therapies Market for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.7. Novel Antibody Therapies Market for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.8. Novel Antibody Therapies Market for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 18.3.9. Novel Antibody Therapies Market for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 18.4. Data Triangulation and Validation

19. NOVEL ANTIBODY THERAPIES MARKET, BY TYPE OF NOVEL ANTIBODY

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Novel Antibody Therapies Market: Distribution by Type of Novel Antibody
  • 19.3.1. Novel Antibody Therapies Market for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 19.3.2. Novel Antibody Therapies Market for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 19.3.3. Novel Antibody Therapies Market for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 19.4. Data Triangulation and Validation

20. NOVEL ANTIBODY THERAPIES MARKET, BY TARGET INDICATION

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Novel Antibody Therapies Market: Distribution by Target Indication
  • 20.3.1. Novel Antibody Therapies Market for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.2. Novel Antibody Therapies Market for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.3. Novel Antibody Therapies Market for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.4. Novel Antibody Therapies Market for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.5. Novel Antibody Therapies Market for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.6. Novel Antibody Therapies Market for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.7. Novel Antibody Therapies Market for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.8. Novel Antibody Therapies Market for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.9. Novel Antibody Therapies Market for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.10. Novel Antibody Therapies Market for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.11. Novel Antibody Therapies Market for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 20.3.12. Novel Antibody Therapies Market for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. NOVEL ANTIBODY THERAPIES MARKET, BY TYPE OF THERAPY

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Novel Antibody Therapies Market: Distribution by Type of Therapy
  • 21.3.1. Novel Antibody Therapies Market for Monotherapy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 21.3.2. Novel Antibody Therapies Market for Combination Therapy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 21.4. Data Triangulation and Validation

22. NOVEL ANTIBODY THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Novel Antibody Therapies Market: Distribution by Route of Administration
  • 22.3.1. Novel Antibody Therapies Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.3.2. Novel Antibody Therapies Market for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 22.4. Data Triangulation and Validation

23. NOVEL ANTIBODY THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Novel Antibody Therapies Market: Distribution by Geographical Regions
  • 23.3.1. Novel Antibody Therapies Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.1.1. Novel Antibody Therapies Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.1.2. Novel Antibody Therapies Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.2. Novel Antibody Therapies Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.1. Novel Antibody Therapies Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.2. Novel Antibody Therapies Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.3. Novel Antibody Therapies Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.4. Novel Antibody Therapies Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2.5. Novel Antibody Therapies Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.3. Novel Antibody Therapies Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.1. Novel Antibody Therapies Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.2. Novel Antibody Therapies Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.3. Novel Antibody Therapies Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.3.4. Novel Antibody Therapies Market in New Zealand, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.4. Novel Antibody Therapies Market in Middle East and North Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.1. Novel Antibody Therapies Market in Egypt, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.2. Novel Antibody Therapies Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.3. Novel Antibody Therapies Market in Iraq, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.4.4. Novel Antibody Therapies Market in Morocco, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 23.4. Novel Antibody Therapies Market, By Geographical Regions: Market Dynamics Assessment
  • 23.4.1. Market Movement Analysis
  • 23.4.2. Penetration-Growth (P-G) Matrix
• 23.5. Data Triangulation and Validation

24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 24.1. Novel Antibody Therapies Market in North America: Distribution by Drugs
  • 24.1.1. Novel Antibody Therapies Market in North America for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.2. Novel Antibody Therapies Market in North America for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.3. Novel Antibody Therapies Market in North America for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.4. Novel Antibody Therapies Market in North America for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.5. Novel Antibody Therapies Market in North America for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.6. Novel Antibody Therapies Market in North America for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.7. Novel Antibody Therapies Market in North America for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.8. Novel Antibody Therapies Market in North America for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.1.9. Novel Antibody Therapies Market in North America for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.2. Novel Antibody Therapies Market in North America: Distribution by Type of Novel Antibody
  • 24.2.1. Novel Antibody Therapies Market in North America for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.2.2. Novel Antibody Therapies Market in North America for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.2.3. Novel Antibody Therapies Market in North America for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.3. Novel Antibody Therapies Market in North America: Distribution by Target Indication
  • 24.3.1. Novel Antibody Therapies Market in North America for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.2. Novel Antibody Therapies Market in North America for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.3. Novel Antibody Therapies Market in North America for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.4. Novel Antibody Therapies Market in North America for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.5. Novel Antibody Therapies Market in North America for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.6. Novel Antibody Therapies Market in North America for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.7. Novel Antibody Therapies Market in North America for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.8. Novel Antibody Therapies Market in North America for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.9. Novel Antibody Therapies Market in North America for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.10. Novel Antibody Therapies Market in North America for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.11. Novel Antibody Therapies Market in North America for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.12. Novel Antibody Therapies Market in North America for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.4. Novel Antibody Therapies Market in North America: Distribution by Type of Therapy
  • 24.4.1. Novel Antibody Therapies Market in North America for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.4.2. Novel Antibody Therapies Market in North America for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.5. Novel Antibody Therapies Market in North America: Distribution by Route of Administration
  • 24.5.1. Novel Antibody Therapies Market in North America for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.5.2. Novel Antibody Therapies Market in North America for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25. MARKET OPPORTUNITY ANALYSIS: EUROPE

• 25.1. Novel Antibody Therapies Market in Europe: Distribution by Drugs
  • 25.1.1. Novel Antibody Therapies Market in Europe for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.2. Novel Antibody Therapies Market in Europe for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.3. Novel Antibody Therapies Market in Europe for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.4. Novel Antibody Therapies Market in Europe for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.5. Novel Antibody Therapies Market in Europe for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.6. Novel Antibody Therapies Market in Europe for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.7. Novel Antibody Therapies Market in Europe for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.8. Novel Antibody Therapies Market in Europe for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.1.9. Novel Antibody Therapies Market in Europe for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.2. Novel Antibody Therapies Market in Europe: Distribution by Type of Novel Antibody
  • 25.2.1. Novel Antibody Therapies Market in Europe for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.2.2. Novel Antibody Therapies Market in Europe for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.2.3. Novel Antibody Therapies Market in Europe for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.3. Novel Antibody Therapies Market in Europe: Distribution by Target Indication
  • 25.3.1. Novel Antibody Therapies Market in Europe for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.2. Novel Antibody Therapies Market in Europe for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.3. Novel Antibody Therapies Market in Europe for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.4. Novel Antibody Therapies Market in Europe for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.5. Novel Antibody Therapies Market in Europe for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.6. Novel Antibody Therapies Market in Europe for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.7. Novel Antibody Therapies Market in Europe for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.8. Novel Antibody Therapies Market in Europe for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.9. Novel Antibody Therapies Market in Europe for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.10. Novel Antibody Therapies Market in Europe for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.11. Novel Antibody Therapies Market in Europe for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.12. Novel Antibody Therapies Market in Europe for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.4. Novel Antibody Therapies Market in Europe: Distribution by Type of Therapy
  • 25.4.1. Novel Antibody Therapies Market in Europe for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.4.2. Novel Antibody Therapies Market in Europe for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.5. Novel Antibody Therapies Market in Europe: Distribution by Route of Administration
  • 25.5.1. Novel Antibody Therapies Market in Europe for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.5.2. Novel Antibody Therapies Market in Europe for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

• 26.1. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Drugs
  • 26.1.1. Novel Antibody Therapies Market in Asia-Pacific for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.2. Novel Antibody Therapies Market in Asia-Pacific for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.3. Novel Antibody Therapies Market in Asia-Pacific for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.4. Novel Antibody Therapies Market in Asia-Pacific for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.5. Novel Antibody Therapies Market in Asia-Pacific for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.6. Novel Antibody Therapies Market in Asia-Pacific for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.7. Novel Antibody Therapies Market in Asia-Pacific for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.8. Novel Antibody Therapies Market in Asia-Pacific for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.1.9. Novel Antibody Therapies Market in Asia-Pacific for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.2. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Type of Novel Antibody
  • 26.2.1. Novel Antibody Therapies Market in Asia-Pacific for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.2.2. Novel Antibody Therapies Market in Asia-Pacific for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.2.3. Novel Antibody Therapies Market in Asia-Pacific for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.3. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Target Indication
  • 26.3.1. Novel Antibody Therapies Market in Asia-Pacific for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.2. Novel Antibody Therapies Market in Asia-Pacific for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.3. Novel Antibody Therapies Market in Asia-Pacific for pcALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.4. Novel Antibody Therapies Market in Asia-Pacific for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.5. Novel Antibody Therapies Market in Asia-Pacific for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.6. Novel Antibody Therapies Market in Asia-Pacific for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.7. Novel Antibody Therapies Market in Asia-Pacific for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.8. Novel Antibody Therapies Market in Asia-Pacific for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.9. Novel Antibody Therapies Market in Asia-Pacific for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.10. Novel Antibody Therapies Market in Asia-Pacific for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.11. Novel Antibody Therapies Market in Asia-Pacific for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.12. Novel Antibody Therapies Market in Asia-Pacific for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.4. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Type of Therapy
  • 26.4.1. Novel Antibody Therapies Market in Asia-Pacific for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 26.4.2. Novel Antibody Therapies Market in Asia-Pacific for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 26.5. Novel Antibody Therapies Market in Asia-Pacific: Distribution by Route of Administration
  • 26.5.1. Novel Antibody Therapies Market in Asia-Pacific for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.5.2. Novel Antibody Therapies Market in Asia-Pacific for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

• 27.1. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Drugs
  • 27.1.1. Novel Antibody Therapies Market in Middle East and North Africa for Adcetris, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.2. Novel Antibody Therapies Market in Middle East and North Africa for for Kadcyla, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.3. Novel Antibody Therapies Market in Middle East and North Africa for for ELZONRIS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.4. Novel Antibody Therapies Market in Middle East and North Africa for for Besponsa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.5. Novel Antibody Therapies Market in Middle East and North Africa for for LYMPHIR, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.6. Novel Antibody Therapies Market in Middle East and North Africa for for Fibromun, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.7. Novel Antibody Therapies Market in Middle East and North Africa for for Nidlegy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.8. Novel Antibody Therapies Market in Middle East and North Africa for for Iomab-B, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.1.9. Novel Antibody Therapies Market in Middle East and North Africa for for TLX 591, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.2. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Type of Novel Antibody
  • 27.2.1. Novel Antibody Therapies Market in Middle East and North Africa for Immunotoxins, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.2.2. Novel Antibody Therapies Market in Middle East and North Africa for Immunocytokines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.2.3. Novel Antibody Therapies Market in Middle East and North Africa for Radioisotope Immunoconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.3. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Target Indication
  • 27.3.1. Novel Antibody Therapies Market in Middle East and North Africa for HER2-PBC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.2. Novel Antibody Therapies Market in Middle East and North Africa for CHL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.3. Novel Antibody Therapies Market in Middle East and North Africa for PCALCL or CD30 MF, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.4. Novel Antibody Therapies Market in Middle East and North Africa for PUSALCL or CD30 PTCL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.5. Novel Antibody Therapies Market in Middle East and North Africa for BPDCN, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.6. Novel Antibody Therapies Market in Middle East and North Africa for RRBPALL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.7. Novel Antibody Therapies Market in Middle East and North Africa for RRCTL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.8. Novel Antibody Therapies Market in Middle East and North Africa for STS, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.9. Novel Antibody Therapies Market in Middle East and North Africa for LAMSM, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.10. Novel Antibody Therapies Market in Middle East and North Africa for RRAML, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.11. Novel Antibody Therapies Market in Middle East and North Africa for DLBL, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.12. Novel Antibody Therapies Market in Middle East and North Africa for MCRPC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.4. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Type of Therapy
  • 27.4.1. Novel Antibody Therapies Market in Middle East and North Africa for Monotherapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 27.4.2. Novel Antibody Therapies Market in Middle East and North Africa for Combination Therapy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 27.5. Novel Antibody Therapies Market in Middle East and North Africa: Distribution by Route of Administration
  • 27.5.1. Novel Antibody Therapies Market in Middle East and North Africa for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.5.2. Novel Antibody Therapies Market in Middle East and North Africa for Intratumoral, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28. NOVEL ANTIBODY THERAPIES MARKET, BY LEADING PLAYERS

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. Novel Antibody Therapies Market: Distribution by Leading Companies
• 28.4. Data Triangulation and Validation

29. TABULATED DATA

30. LIST OF COMPANIES AND ORGANIZATIONS